HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

Ping An Healthcare and Technology / Equity Bottom-Up

<ul>
<li>In 2025, the NHSA will continue to deepen the VBP of drugs and centralized procurement of medical consumables, covering 700 drug varieties in total. </li>
<li>Valuation of the entire industry has been sluggish for three years. With the positive changes, we think it is the time to be optimistic on China healthcare in 2025.</li>
<li>Due to the craze for DeepSeek/AI, PAGD's stock price surged.Although this is a great story, the extent to which DeepSeek can bring substantial benefits to PAGD remains to be verified.</li>
</ul>


In 2025, the NHSA will continue to deepen the VBP of drugs and centralized procurement of medical consumables, covering 700 drug varieties in total. 
Valuation of the entire industry has been sluggish for three years. With the positive changes, we think it is the time to be optimistic on China healthcare in 2025.
Due to the craze for DeepSeek/AI, PAGD's stock price surged.Although this is a great story, the extent to which DeepSeek can bring substantial benefits to PAGD remains to be verified.


China Healthcare Weekly (Feb.23)-Ping An Good Doctor Shares Surge, China Healthcare Has Bottomed Out

<ul>
<li>Through Special Dividend, Ping An has achieved its initial plan at a low price. Ping An ruled out the possibility of privatization, which could be due to the high cost.</li>
<li>Ping An may hope to further leverage the synergies, increase resource tilt towards PAGD, thereby helping it out of the trough.But we’re not optimistic due to PAGD’s problematic business model.</li>
<li>The gap between PAGD and JD Health/Alibaba Health will continue to widen. Based on our forecast, we think PAGD is overvalued. Its valuation should be lower than JD Health/Alibaba Health.</li>
</ul>


Through Special Dividend, Ping An has achieved its initial plan at a low price. Ping An ruled out the possibility of privatization, which could be due to the high cost.
Ping An may hope to further leverage the synergies, increase resource tilt towards PAGD, thereby helping it out of the trough.But we’re not optimistic due to PAGD’s problematic business model.
The gap between PAGD and JD Health/Alibaba Health will continue to widen. Based on our forecast, we think PAGD is overvalued. Its valuation should be lower than JD Health/Alibaba Health.


Ping An Healthcare and Technology (1833.HK) - Thoughts About The Mandatory General Offer and Outlook

Blue Lotus Research Institute

Andy Fu

China growth and global non-US Internet equities

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

<ul>
<li>O2O has made a huge impact on China's e-commerce scene in 2024. The Coupang-invented model suits mega cities with dense population and order volumes;</li>
<li>Online drug O2O, in particular, has gained momentum because drugs, prescription and non-prescription have robust storage and distribution needs on the ground for O2O use;</li>
<li>Meituan's drug sales has grown its overall market share from 3.6% in 2022 to 7.1% in 2024. We project it to grow to 12.3% by 2030. </li>
</ul>


O2O has made a huge impact on China's e-commerce scene in 2024. The Coupang-invented model suits mega cities with dense population and order volumes;
Online drug O2O, in particular, has gained momentum because drugs, prescription and non-prescription have robust storage and distribution needs on the ground for O2O use;
Meituan's drug sales has grown its overall market share from 3.6% in 2022 to 7.1% in 2024. We project it to grow to 12.3% by 2030. 


Meituan (3690 HK): Online Drug Sales Is the First Sweet Spot of O2O Vs. E-Commerce

Equity Capital Markets

<ul>
<li>The two core businesses is corporate and digital marketing services (2B business) and health and medical services (2C business),the synergy of which can form a virtuous cycle within the platform.</li>
<li>The key performance driver for HealthWay is 2B business, but the pain point is 2C business, which is hard to scale up. Actually, HealthyWay’s growth momentum has slowed down significantly.</li>
<li>After completing the final round of financing, HealthyWay’s valuation reached RMB4.1 billion. We think its valuation could be higher than ClouDr but lower than JD Health and Alibaba Health.</li>
</ul>


The two core businesses is corporate and digital marketing services (2B business) and health and medical services (2C business),the synergy of which can form a virtuous cycle within the platform.
The key performance driver for HealthWay is 2B business, but the pain point is 2C business, which is hard to scale up. Actually, HealthyWay’s growth momentum has slowed down significantly.
After completing the final round of financing, HealthyWay’s valuation reached RMB4.1 billion. We think its valuation could be higher than ClouDr but lower than JD Health and Alibaba Health.


Pre-IPO HealthyWay (PHIP Updates) - Some Points Worth the Attention

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of December 6th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Alibaba, CCB, Sunny Optical, Xpeng, CMB.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of December 6th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Alibaba, CCB, Sunny Optical, Xpeng, CMB.


Hong Kong Connect Flows (Dec 6th): Alibaba, CCB, Sunny Optical, Xpeng, CMB

China

JD Health International Inc. operates drug stores. The Company retails Chinese and Western medicines, nutrition products, health care products, and other products. JD Health International markets its products throughout China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

JD Health International (6618 HK)

China Healthcare Weekly (Feb.23)-Ping An Good Doctor Shares Surge, China Healthcare Has Bottomed Out

NHSA to expand VBP in 2025. China healthcare has entered the stage of bottoming out from 2025.The extent to which DeepSeek can bring substantial...

Xinyao (Criss) Wang

Ping An Healthcare and Technology (1833.HK) - Thoughts About The Mandatory General Offer and Outlook

The current stock price performance of Ping An Good Doctor (PAGD) significantly underperforms peers JD Health and Alibaba Health. As analyzed, due...

Xinyao (Criss) Wang

Meituan (3690 HK): Online Drug Sales Is the First Sweet Spot of O2O Vs. E-Commerce

O2O revolutionizes China's e-commerce, especially in online drug sales with Meituan leading the way to significant market share growth. The share...

Blue Lotus Research Institute

Pre-IPO HealthyWay (PHIP Updates) - Some Points Worth the Attention

The key growth driver of HealthyWay is 2B business, but the company is facing challenge in scaling up its 2C business. Pre-IPO valuation reached...

Xinyao (Criss) Wang

Hong Kong Connect Flows (Dec 6th): Alibaba, CCB, Sunny Optical, Xpeng, CMB

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, CCB, Sunny Optical, Xpeng, CMB.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

China Healthcare Weekly (Feb.23)-Ping An Good Doctor Shares Surge, China Healthcare Has Bottomed Out

​NHSA to expand VBP in 2025. China healthcare has entered the stage of bottoming out from 2025.The extent to which DeepSeek can bring substantial...

Xinyao (Criss) Wang

Ping An Healthcare and Technology (1833.HK) - Thoughts About The Mandatory General Offer and Outlook

The current stock price performance of Ping An Good Doctor (PAGD) significantly underperforms peers JD Health and Alibaba Health. As analyzed, due...

Xinyao (Criss) Wang

Meituan (3690 HK): Online Drug Sales Is the First Sweet Spot of O2O Vs. E-Commerce

​O2O revolutionizes China's e-commerce, especially in online drug sales with Meituan leading the way to significant market share growth. The share...

Blue Lotus Research Institute

Pre-IPO HealthyWay (PHIP Updates) - Some Points Worth the Attention

The key growth driver of HealthyWay is 2B business, but the company is facing challenge in scaling up its 2C business. Pre-IPO valuation reached...

Xinyao (Criss) Wang

Hong Kong Connect Flows (Dec 6th): Alibaba, CCB, Sunny Optical, Xpeng, CMB

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Alibaba, CCB, Sunny Optical, Xpeng, CMB.

Ke Yan, CFA, FRM

NHSA to expand VBP in 2025. China healthcare has entered the stage of bottoming out from 2025.The extent to which DeepSeek can bring substantial...

O2O revolutionizes China's e-commerce, especially in online drug sales with Meituan leading the way to significant market share growth. The share...